Supernus Pharmaceuticals Inc (SUPN)
Fixed asset turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 661,817 | 654,387 | 632,578 | 598,906 | 607,521 | 619,414 | 641,163 | 674,751 | 673,056 | 651,277 | 618,187 | 585,808 | 560,079 | 545,016 | 551,524 | 536,576 | 506,717 | 465,383 | 418,476 | 402,257 |
Property, plant and equipment | US$ in thousands | 11,545 | 11,876 | 12,274 | 12,969 | 13,530 | 13,688 | 14,186 | 14,611 | 15,173 | 15,872 | 16,317 | 17,215 | 16,955 | 16,471 | 17,065 | 37,950 | 37,824 | 17,395 | 17,941 | 18,011 |
Fixed asset turnover | 57.32 | 55.10 | 51.54 | 46.18 | 44.90 | 45.25 | 45.20 | 46.18 | 44.36 | 41.03 | 37.89 | 34.03 | 33.03 | 33.09 | 32.32 | 14.14 | 13.40 | 26.75 | 23.33 | 22.33 |
December 31, 2024 calculation
Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $661,817K ÷ $11,545K
= 57.32
Supernus Pharmaceuticals Inc's fixed asset turnover has shown a consistent upward trend over the past few years, indicating improved efficiency in generating revenue from its fixed assets. The ratio has increased steadily from 22.33 in March 2020 to 57.32 in December 2024. This signifies that the company is utilizing its fixed assets more effectively to generate sales, which is a positive sign of operational efficiency and asset utilization.
The significant increase in fixed asset turnover from 2020 to 2024 suggests that Supernus Pharmaceuticals Inc has been able to increase its revenue generation relative to its investment in fixed assets. A higher fixed asset turnover ratio implies that the company is generating more sales per dollar invested in fixed assets, which is favorable for profitability and overall financial performance.
Overall, the improving trend in fixed asset turnover reflects well on Supernus Pharmaceuticals Inc's operational efficiency and productivity in utilizing its fixed assets to drive revenue growth. This could indicate effective management of assets and resources within the company, leading to a stronger financial position and potential for sustainable growth in the future.
Peer comparison
Dec 31, 2024